Comparative Pharmacology
Head-to-head clinical analysis: SODIUM FLUORIDE F 18 versus XOFIGO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM FLUORIDE F 18 versus XOFIGO.
SODIUM FLUORIDE F-18 vs XOFIGO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Positron-emitting radionuclide used for bone imaging; fluoride ion is incorporated into bone matrix via chemisorption onto hydroxyapatite crystals, reflecting blood flow and osteoblastic activity.
Radium-223 dichloride is a calcium-mimetic alpha particle-emitting radiopharmaceutical that forms complexes with bone mineral hydroxyapatite at areas of increased bone turnover, such as bone metastases. The alpha particles induce double-strand DNA breaks in adjacent cells, resulting in cytotoxic effects.
2-10 mCi (74-370 MBq) intravenous bolus injection, single dose for positron emission tomography (PET) bone imaging.
55 kBq (1.49 microcurie) per kg body weight, intravenous injection every 4 weeks.
None Documented
None Documented
The terminal elimination half-life is approximately 2-4 hours. Clinically, this allows for imaging within 1-3 hours post-injection.
The terminal elimination half-life of radium-223 dichloride is approximately 11 days (range 7–14 days), reflecting the slow turnover of radium in bone.
Renal (primarily). Approximately 70% of the administered dose is excreted unchanged in urine within 24 hours. Less than 10% is excreted in feces.
Radium-223 dichloride is primarily excreted via the feces. Approximately 75% of the administered dose is eliminated in feces within 7 days, with a smaller fraction (about 5%) excreted in urine.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical